Endoscopic lung volume reduction: hype or hope?

Mordechai Kramer1, Oren Fruchter1, Moshe-Nimrod Maimon2, Yael Refaely3.

1Pulmonary and Critical Care Medicine, Bellion Hospital, Rubin Medical Center, Petach Tikva, Israel; 2Pulmonary Medicine, Soroka Medical Center, Be’er-Sheva, Israel; 3Thoracic Surgery, Soroka Medical Center, Be’er-Sheva, Israel.

Objective(s): This open labeled multicenter study was performed to evaluate the safety and efficacy of single-session bilateral 4-site lung volume reduction therapy with the AeriSeal® Emphysematous Lung Sealant System (ELS) in patients with advanced upper lobe heterogeneous (ULP) and homogeneous (Ho) emphysema.

Methods: 20 patients with advanced Ho (n=4) and ULP (n=16) emphysema received 4-site bilateral upper lobe volume reduction with ELS under conscious sedation. Outcome measures include pulmonary function tests (at 6, 12 and 24 wks), exercise capacity, symptoms, and health related quality of life (HRQL, at 12 and 24 wks).

Results: 4-site therapy was well tolerated. Procedure duration was 14±4 minutes. Average hospital length of stay was 0.9±1.5 days. There were 5 SAEs during the first 85±32 days of follow-up (3 treatment related, 1 COPD exacerbation). Interim 6-week results (n=14; ΔFEV1 = +16.1±27.5%; ΔFVC = +10.7±17.4%) demonstrated clinically significant improvements in spirometry (Δ = +12%) in 8 of 14 patients. 12 week data for the first 4 patients demonstrated additional physiological improvement (ΔFEV1 = +37.6%; ΔFVC = +14.1%) from their corresponding 6-week responses (ΔFEV1 = +17.1%; ΔFVC = 8.2%).

Conclusions: Bilateral single session endoscopic lung volume reduction therapy can be achieved safely using ELS in patients with advanced Ho and ULP emphysema under conscious sedation. Initial results indicate that efficacy responses are similar to those reported with surgical volume reduction, and treatment is associated with short hospital length of stay and minimal morbidity.
370 Sustained efficacy from 3 to 6 months following bronchoscopic thermal volumetric ablation (BTVA) in the treatment of heterogeneous emphysema
Felis Herth1, Gregory Snell2, Peter Hopkins3, Kim Baker4, Christian Wün4, Mark H. Gottfried4, Arshag Valipour5, Manfred Wagner6, Franz Stanzel7, Jun Egan8, Steven Kesten9, Armin Ernst10, 1Pneumology and Critical Care Medicine, Thoraxklinik Heidelberg, Heidelberg, Germany; 2Allergy Immunology & Respiratory Medicine, The Alfred Hospital, Melbourne, Australia; 3Lung Transplant Unit, Prince Charles Hospital, Chermside, Australia; 4Pulmonary and Critical Care Medicine, University of Iowa, Iowa City, United States; 5Pneumology, Charité Campus-Mitte, Berlin, Germany; 6Pulmonary Associates, Campus Charite Mitte, Berlin, Germany; 7Pneumologie, Klinikum Nürnberg, Nürnberg, Germany; 8Pneumologie, Zentrum für Pneumologie, Hemer, Germany; 9Pneumologie, St. Pierre Hospital, Brussels, Belgium; 10Advanced Lung Disease Program, Mater Misericordiae University Hospital, Dublin, Ireland; 11Clinical Department, Upstate Medical Corp, Syracuse, United States; 12Pulmonary Critical Care and Sleep Medicine, Caritas St. Elizabeth’s Medical Center, Boston, United States

Background: A recent approach to bronchoscopic lung volume reduction (LVR), BTVA, involves the localized application of thermal energy through heated water vapor to targeted areas of emphysematous lung in order to induce LVR.

Objectives: Evaluate efficacy and safety of BTVA in the treatment of heterogeneous emphysema during a clinical trial.

Methods: Open-label, single-arm trial of BTVA in patients with upper lobe predominant emphysema (n=44). Entry criteria: FEV1 15% - 45% predicted, RV >100%, TLC >140 cm, DLOC >20%, previous pulmonary re-habilitation. Primary efficacy endpoint: FEV1 and SGRQ at 6 months. Other endpoints included FVC, RV, FRC, TLC, mMRC dyspnea, 6MWD.

Results: No procedural complications (mean procedure time:30 min). Lung function changes from baseline (mean (SE)) are summarized in the following table:

<table>
<thead>
<tr>
<th>variable</th>
<th>baseline</th>
<th>1 year+</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>FEV1 (ml)</td>
<td>1.13 ± 0.9</td>
<td>2.95 ± 0.75</td>
<td>0.018</td>
</tr>
<tr>
<td>forced expiratory volume in 1 second (FEV1)</td>
<td>1.13 ± 0.9</td>
<td>2.95 ± 0.75</td>
<td>0.018</td>
</tr>
<tr>
<td>forced vital capacity (FVC)</td>
<td>3.48 ± 0.8</td>
<td>5.79 ± 0.78</td>
<td>0.001</td>
</tr>
<tr>
<td>forced vital capacity (FVC)</td>
<td>3.48 ± 0.8</td>
<td>5.79 ± 0.78</td>
<td>0.001</td>
</tr>
<tr>
<td>forced expiratory volume in 1 second (FEV1)</td>
<td>9.40 ± 3.3</td>
<td>9.40 ± 3.3</td>
<td>0.35</td>
</tr>
<tr>
<td>FEV1 (l)</td>
<td>9.40 ± 3.3</td>
<td>9.40 ± 3.3</td>
<td>0.35</td>
</tr>
<tr>
<td>SGRQ (scale 0 to 100)</td>
<td>59.9 ± 6.3</td>
<td>50.7 ± 6.3</td>
<td>0.018</td>
</tr>
<tr>
<td>mMRC (scale 0 to 4)</td>
<td>2.9 ± 1.1</td>
<td>2.0 ± 1.0</td>
<td>0.0003</td>
</tr>
<tr>
<td>6MWT (meters)</td>
<td>367 ± 97</td>
<td>374 ± 137.4</td>
<td>0.89</td>
</tr>
<tr>
<td>PO2 (mmHg)</td>
<td>65 ± 8.6</td>
<td>67.6 ± 9.7</td>
<td>0.19</td>
</tr>
<tr>
<td>6MWD (scale)</td>
<td>5.5 ± 1.6</td>
<td>4.7 ± 2.3</td>
<td>0.05</td>
</tr>
</tbody>
</table>

Conclusions: Improvements with IBV Valve treatment are sustained after 1 year. Subjects with advanced emphysema have a fast slope of decline however, palliative treatments with bronchial valves could affect the natural course of this disease.

371 Lung volume reduction coil treatment for patients with severe heterogeneous emphysema, a multicenter feasibility trial
Dirk-Jan Siebel1, Karin Klooster1, Martin Hetzel2, Franz Stanzel2, Gaetan Deleze1, Christian Wün3, Wolfgang Giesebrecht4, Romain Kessler5, Michael Pfeifer6, Stefan Blas6, Jürgen Hetzel7, Charles-Hugo Marquet7, Felix Herth1, 1Pneumologie, UMC-Groningen, Groningen, Netherlands; 2Pneumologie, Krankenhaus vroen Roten Kreuz, Stuttart, Germany; 3Lungenklinik, Lungenklinik, Hemer, Hemer, Germany; 4Pulmonary Diseases, Hospital Maison Blanche CHU Reims, Reims, France; 5Pulmonary Diseases, Campus Charite Mitte, Berlin, Germany; 6Pulmonary Diseases, Hospital Pasteur, CHU Nice, Nice, France; 7Pulmonary Diseases, Thoraxklinik, Heidelberg, Germany

Introduction: The Lung Volume Reduction Coil (LVRC) is a bronchoscopic device made of self-expandable nitinol wire for the treatment of emphysema. A previous single center pilot study showed safety and efficacy in severe upper-lobe emphysema.

Aims: In this study we investigated the feasibility, safety and efficacy of LVRC treatment in a multicenter cohort trial design in patients with severe upper or lower lobe heterogeneous emphysema.

Methods: 44 patients (23F/21M, 60yrs (± 11), FEV1 29.9%pred (±8.6), RV 249g%pred (±52%), TLC 135%p (±16%) were bronchoscopically treated under general anesthesia using fluoroscopy with LVRCs (PneumRx, USA) in either one or two lungs (in two sequential procedures) in 10 European centers. Safety was evaluated by recording all of adverse events (AEs). Efficacy as measured by questionnaires, pulmonary function- and exercise testing will be measured at 3, 6 and 12 months post treatment.

Results: 83 LVRC procedures were performed (39 bilateral, 5 unilateral). 33 patients were treated in the upper lobes and 11 in the lower lobes. The mean procedure time was 50 mins (4:24), using a median of 10 coils (range 8-14) per lobe. The coil lengths used were 70mm (2x), 85mm (19x), 100mm (35x), 125mm (34x), 150mm (81x) and 175mm (25x). AEs <24hrs after the procedure were: COPD exacerbation (n=2), pneumothorax (n=1), chest pain (n=2), dyspnea (n=3), consolidation (n=1), cough (n=1), and mild hemoptysis (n=5).

Conclusion: The LVRC treatment is technically feasible in both upper and lower lobe emphysema, with a good periprocedural safety profile. At the ERS conference we will also be able to present the follow-up efficacy and safety data for this trial.

372 One year follow-up in the European multicenter study for the treatment of advanced emphysema with bronchial valve
Vincent Ninane1, Michela Bezzz2, Christian Gelmer3, Xavier Gonzalez4, 1Respiratory Medicine, St. Pierre Hospital, Brussels, Belgium; 2Respiratory Medicine, Hospedale Civile di Brescia, Brescia, Italy; 3Respiratory Medicine, LHJ Natters, Innsbruck, Austria; 4Clinical Research, Spritum Inc, Redmond, WA, United States

We have reported positive results of a blinded and randomized sham bronchoscopy controlled study that evaluated the IBV® Valve System (Spiration Inc.) in subjects with advanced upper lobe predominant emphysema. After a 3-month evaluation, subjects in the treatment and sham control groups were un-blinded. Then, the control group was allowed to receive valve treatment. In 3 of the 7 centers participating in the study, Ethics approval was obtained for an additional evaluation at approximately 1 year of treatment.

Methods: After approximately one year of receiving valves, the evaluations included physical examination, imaging (CT scan to evaluate regional volumetric changes), pulmonary function, questionnaires, exercise and blood gases.

Results: All subjects were in stable condition, and satisfied with the outcome. Complete data for paired analysis was available in 25 of 29 subjects that returned for the evaluation. The average time for the evaluations was 13.5±1.3 months. Results are summarized in a table format.

Conclusions: Improvements with IBV Valve treatment are sustained after 1 year. Subjects with advanced emphysema have a fast slope of decline however, palliative treatments with bronchial valves could affect the natural course of this disease.

373 Study of the use of Chiesi’s pulmonary assessment system to optimize subject selection for endobronchial lung volume reduction (ELVR) – Results and subgroup analysis
Daniela Gompelmann1, Dirk-Jan Siebel2, Joachim Ficker3, Frank Reichenberger4, Bernd Schmidt5, Lars EK3, Ralf Eberhard3, 1Pneumology, Thoraxklinik at University Hospital, Heidelberg, Germany; 2Pneumologie, University Medical Center, Groningen, Netherlands; 3Pulmonology, Klinikum Nürnberg, Nürnberg, Germany; 4Pneumologie, University Hospital, Giessen, Germany; 5Pneumologie, University Hospital, Hallie, Germany; 6Pneumologie, University Hospital, Land, Sweden

Introduction: Collateral ventilation (CV) has been shown to prevent lung volume reduction (LVR) after Endobronchial Valve (EBV) treatment. Direct measurement of CV may predict patients who will achieve significant LVR. The Chiesi® Pulmonary Assessment System quantifies the average collateral resistance. When the resistance value ≤ 10, the patient is “CV Negative,” when the resistance value ≥10, the patient is “CV Positive.”

Abstract printing supported by Chiesi. Visit Chiesi at Stand D.30
Objective: To evaluate the effectiveness of the Chartis® system in predicting subjects with heterogeneous emphysema who will achieve significant (≥350mL) LVR from EBV therapy.

Methods: Patients with heterogeneous emphysema were enrolled. Following Chartis assessment of the targeted lobe, that was determined by using HRCT, all patients were treated with Zephyr® EBV. Primary endpoint was HRCT-measured LVR in the treated lobe at 30 days. FEV1, SGRQ and 6MWT were evaluated as secondary endpoints.

Results: To date, primary endpoint is collected for 24 patients. Primary and Secondary Endpoints for 75-80 patients are anticipated. Subgroup analyses will focus on patient selection criteria.

Conclusion: Chartis System predicts significant LVR after EBV treatment. Results suggest that expanded patient selection criteria will enable successful treatment for a broader population of emphysema patients.

6-month follow-up in patients with advanced homogeneous emphysema treated with endobronchial lung sealant therapy

Arscang Valipour1, Felix Herth2, Ralf Eberhardt2, Franz Stanzl3, Reiner Bonnet4, Jurgen Behr5, Charles Marquette6, Mondechai Kramer7.

1 Respiratory and Critical Care Medicine, Otto Wagner Hospital, Vienna, Austria; 2 Pneumology and Critical Care, Thoraxklinik University of Heidelberg, Heidelberg, Germany; 3 Pneumology II and Endoscopy Service, Lungenklinik Hemer, Hemer, Germany; 4 Pneumology, Zentralklinik Bad Berka GmbH, Bad Berka, Germany; 5 Medizinischer Klinik III, University Bergmannsheil, Bochum, Germany; 6 Service of Pneumology, Hospital Pasteur University of Nice, Nice, France; 7 Pulmonary and Critical Care Medicine, Rubin Medical Center, Bellinson Hospital, Petach Tikva, Israel

Objective(s): Bronchoscopic lung volume reduction therapy using endobronchial valves (Scurba F et al., NEJM, 2010;363) and coils (Herth FJ et al. Therap Adv Respir Dis, 2010;4) has shown limited efficacy in patients with advanced homogeneous emphysema (AHoE). This study summarizes responses to AeriSeal® Emphysematous Lung Sealant (ELS) therapy in patients with AHoE out to 6 months.

Methods: Patients with AHoE and scintigraphy scans showing reduced perfusion to the upper lung zones (n=12) were included in this study, which was performed at 8 investigational centers in Europe and Israel. All patients received initial 2-site upper lobe bronchoscopic ELS therapy; approximately 2/3 received a second site upper lobe bronchoscopic ELS therapy; approximately 2/3 received a second treatment at 2 additional sites in the contralateral lung. Follow-up was performed at 3 and 6 months post treatment.

Results: Upper lobe ELS therapy in this cohort of AHoE patients (8 male, age 64±7 yrs) was well tolerated, and was associated with improvements in pulmonary function, functional capacity, and quality of life. Three (3) and 6 month changes in FEV1 (+12.6±13.1%; 9.5±13.9%), FVC (8.1±12.1%; 8.6±13.1%), RV/TLC ratio (-3.6±8.7%; -5.1±8.3%), MRCD (+0.2±0.83); -0.4±0.90), 6MWT (+15.4±45.5m; +16.6±47.7m), and SGRQ (-7.9±17.6%; -13.3±23.0%) were observed. MCID improvements in spirometry (>12% improvement in FEV1 and/or FVC) were observed in ≥50% of patients at both time points.

Conclusion: ELS therapy produces durable improvements in pulmonary function and quality of life in patients with AHoE, and represents a new therapeutic option for patients with homogeneous emphysema who remain symptomatic despite maximal medical therapy.

375 Efficiency of the endo-bronchial volum reduction treatment for severe heterogeneous emphysema

Turhan Ece1, Aysen Erer1, Zuleyha Bingol1, Tuğçe Hurkal2, Alper Toker3, Ferah Ece4, 1 Pulmonary Department, Istanbul University Istanbul Medical Faculty, Istanbul, Turkey; 2 Pulmonary Department, Istanbul Bilim University, Istanbul, Turkey; 3 Thoracic Surgery Department, Istanbul University Istanbul Medical Faculty, Istanbul, Turkey

Background: Patients with advanced chronic obstructive pulmonary disease (COPD) have limited treatment options. Exercise capacity and health related quality of life (HRQL) of the patients are affected by the progress of respiratory failure. Volum reduction surgery is reported to be effective for selected patients with severe COPD. But there is a high risk for the surgery of these patients with hypoxemia hypercapnia. Endo-bronchial volum reduction treatment (EBVRT) by a valve application which is a minimally invasive method has been come up for these patients.

Method: To study the safety and effectiveness of the EBVRT for heterogeneous emphysema.

Result: EBVRT were applied to 21 patients. Most of the patients were male (66.6%). Valves were placed into upper lobe (n=15), lower lobes (n=5) and middle lobe (n=1). There were no procedure-related deaths. Only one patient with ischemic heart disease was died at the 3rd month. Device related complication was occurred in two patients; one patient was intubated and the other patient’s valve was occluded and worked inversely. Functional capacity was improved in 71% (n=15) of the patients but only 66% (n=10) of these patients were feeling and doing better. In these patients mean 10mmHG increase of PaO2 and mean 4.5mmHG decrease of PaCO2 were observed at 3rd month. HRQL were improved in 48% (n=10) of the patients. However, pulmonary functions, 6 minute walking distance were not significantly changed.

Conclusion: Although FEV1, 6 minute walking distance were not changed, PaO2, functional status and HRQL improvement were observed with EBVRT of advanced emphysema patients. EBVRT is a new method with acceptable safety for the patients with severe COPD.